Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

bluebird bio’s beti-cel accepted for priority review by FDA

bluebird bio’s beti-cel accepted for priority review by FDA

The tough journey to approval for beta-thalassemia gene therapy (beti-cel) in the US may be coming to an end, with approval possible by 2022. ... The one-off gene therapy is for adult, adolescent and paediatric patients with beta-thalassemia across all

Latest news

More from news
Approximately 14 fully matching, plus 341 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

More from appointments
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 19 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...